Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors.
The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Thomas Jensen |
Contact Details
Address: 24 School Street, 2nd Floor Boston, Massachusetts 02108 United States | |
| Phone | 401 426 4664 |
| Website | allarity.com |
Stock Details
| Ticker Symbol | ALLR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001860657 |
| CUSIP Number | 016744500 |
| ISIN Number | US0167445008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer and Director |
| Dr. Steen Meier Knudsen Ph.D. | Founder and Chief Scientific Officer |
| Dr. Jeremy R. Graff Ph.D. | President and Chief Development Officer |
| Alexander Epshinsky CPA | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 7, 2025 | 8-K | Current Report |